Luveris (Lutropin Alfa)
Recombinant human luteinizing hormone for fertility treatment
Quick Facts About Luveris
Key Takeaways About Luveris
- What it is: Luveris is a recombinant luteinizing hormone (LH) used alongside FSH to stimulate follicular development in women with severe hormone deficiency
- How it is used: Given as a daily subcutaneous injection (75 IU) together with FSH for up to 3-5 weeks during controlled ovarian stimulation
- Key warning: Ovarian hyperstimulation syndrome (OHSS) is a potential complication requiring close monitoring with ultrasound and blood tests
- Multiple pregnancy risk: Treatment increases the chance of twins or higher-order multiples compared to natural conception
- Specialist supervision required: Treatment must be initiated and monitored by a physician experienced in fertility treatment
What Is Luveris and What Is It Used For?
Luveris (lutropin alfa) is a recombinant human luteinizing hormone (LH) used in fertility treatment to stimulate follicular development in women with severe LH and FSH deficiency. It is always used together with follicle-stimulating hormone (FSH) and is followed by a single injection of human chorionic gonadotropin (hCG) to trigger ovulation.
Luveris contains lutropin alfa, a protein that is virtually identical to naturally occurring human luteinizing hormone (LH). It is manufactured using advanced recombinant DNA technology, which means it is produced by genetically engineered cells rather than being extracted from human urine. This manufacturing process ensures high purity and batch-to-batch consistency.
Luteinizing hormone belongs to the gonadotropin family of hormones, which play a central role in regulating the reproductive cycle. In a normal menstrual cycle, the pituitary gland releases both LH and FSH. These two hormones work in concert to stimulate the ovaries: FSH drives the growth and maturation of follicles, while LH stimulates the theca cells to produce androgens that are subsequently converted into estradiol by granulosa cells. Without adequate LH, FSH alone cannot support normal follicular development.
Luveris is specifically recommended for adult women who produce very low levels of both LH and FSH, a condition known as hypogonadotropic hypogonadism. In these patients, the pituitary gland fails to secrete sufficient gonadotropins to drive normal ovarian function. By providing exogenous LH alongside FSH (such as follitropin alfa), Luveris helps restore the hormonal environment needed for a follicle to grow and mature properly.
Once adequate follicular development has been achieved (as confirmed by ultrasound and estradiol measurements), a single dose of human chorionic gonadotropin (hCG) is administered. hCG mimics the natural LH surge that triggers ovulation, causing the mature follicle to release its egg. The patient is then advised to have intercourse on the day of the hCG injection and the following day, or an assisted reproductive technology (ART) procedure such as intrauterine insemination (IUI) or in vitro fertilization (IVF) may be performed.
What Should You Know Before Taking Luveris?
Luveris must not be used in women with ovarian, uterine or breast cancer, unexplained vaginal bleeding, ovarian cysts of unknown origin, or hypersensitivity to gonadotropins. A thorough fertility evaluation should be completed before starting treatment, and conditions that preclude a normal pregnancy should be ruled out.
Contraindications
Luveris must not be used in the following circumstances:
- Allergy to gonadotropins: If you are allergic to luteinizing hormone, follicle-stimulating hormone, human chorionic gonadotropin, or any of the excipients in Luveris
- Hormone-sensitive cancers: Ovarian cancer, uterine cancer, or breast cancer are absolute contraindications
- Brain tumors: A history of pituitary or hypothalamic tumors (unless the tumor has been treated and gonadotropin deficiency is the specific indication)
- Enlarged ovaries or ovarian cysts: Ovarian enlargement or cysts of unknown origin that are not related to polycystic ovary syndrome
- Unexplained vaginal bleeding: Any uterine bleeding that has not been properly investigated
If any of the above conditions apply to you, it is essential that you inform your doctor before starting treatment. Your fertility specialist will conduct a thorough evaluation to ensure that Luveris is appropriate for your situation.
Warnings and Precautions
Before starting treatment with Luveris, both your fertility and that of your partner should be thoroughly evaluated. Your doctor will take a detailed medical history and may perform blood tests, imaging studies, and a semen analysis for your partner.
Luveris is not recommended if you have any condition that would normally make a healthy pregnancy impossible, such as primary ovarian insufficiency (premature ovarian failure), reproductive tract malformations, or uterine fibroids that would interfere with implantation.
Ovarian Hyperstimulation Syndrome (OHSS)
Ovarian hyperstimulation syndrome (OHSS) is the most significant risk associated with gonadotropin therapy. In OHSS, the ovaries over-respond to stimulation, leading to the formation of multiple large follicles and cysts. Fluid can shift from the bloodstream into the abdominal cavity and, in severe cases, into the chest cavity. Symptoms range from mild abdominal discomfort and bloating to severe pain, rapid weight gain, nausea, vomiting, shortness of breath, and in rare cases, thromboembolic events.
The risk of OHSS is minimized by careful dose titration and regular monitoring. Your doctor will perform transvaginal ultrasound examinations and measure serum estradiol levels throughout the treatment cycle. If the ovarian response is excessive, the hCG trigger injection will be withheld, which effectively prevents OHSS from progressing. In such cycles, you will be advised to use barrier contraception or abstain from intercourse for at least four days.
Adherence to the recommended dosing schedule significantly reduces the likelihood of OHSS. Severe OHSS is uncommon with Luveris therapy alone but becomes more probable if hCG is administered when ovarian response is excessive.
Multiple Pregnancy
When using Luveris and other gonadotropins, the risk of becoming pregnant with more than one baby (multiple pregnancy, most commonly twins) is higher than with natural conception. Multiple pregnancies carry increased medical risks for both the mother and the babies, including preterm delivery, low birth weight, pre-eclampsia, and gestational diabetes.
The risk of multiple pregnancy can be reduced by using the lowest effective dose of gonadotropins and by careful monitoring of the number of developing follicles. In assisted reproductive technology (ART) cycles, the risk is also related to the number of embryos transferred. Your fertility specialist will discuss the optimal strategy to minimize the chance of higher-order multiples while maximizing your chances of a successful pregnancy.
Pregnancy and Breastfeeding
Luveris must not be used during pregnancy or while breastfeeding. If you suspect you may be pregnant, stop using Luveris and contact your doctor immediately. There is no clinical indication for LH supplementation once pregnancy has been established.
Other Important Risks
Miscarriage: The rate of miscarriage following assisted reproduction or ovarian stimulation is somewhat higher than in spontaneous conception. This may be related to the underlying infertility, patient age, or the ART procedure itself rather than to the medications used.
Ectopic pregnancy: Women with a history of tubal disease are at increased risk of ectopic pregnancy (where the embryo implants outside the uterus), regardless of whether pregnancy was achieved naturally or with fertility treatment. Early ultrasound monitoring is performed to confirm intrauterine pregnancy location.
Blood clots (thromboembolism): Tell your doctor before starting treatment if you or a family member has ever had a blood clot in the leg or lung, a heart attack, or a stroke. Gonadotropin therapy, particularly when complicated by OHSS, may increase the risk of venous thromboembolism.
Porphyria: If you or anyone in your family has porphyria (a group of disorders affecting heme synthesis), inform your doctor before beginning treatment, as gonadotropins may trigger acute porphyric attacks in susceptible individuals.
Congenital malformations: The rate of congenital malformations following assisted reproduction may be slightly higher than after spontaneous conception. This is thought to be related to parental factors (such as maternal age and genetic background) as well as the ART procedures themselves, rather than the specific medications used.
How Does Luveris Interact with Other Drugs?
Luveris has no known clinically significant drug-drug interactions. It is routinely combined with follitropin alfa (FSH) in the same injection and is followed by hCG to trigger ovulation. Do not mix Luveris with any other medications in the same syringe except follitropin alfa as directed by your doctor.
Because Luveris is a recombinant protein hormone administered by subcutaneous injection, it does not undergo hepatic metabolism and is not expected to interact with cytochrome P450-mediated drug metabolism pathways. Clinical experience and pharmacokinetic studies have not identified significant interactions between lutropin alfa and other commonly used medications.
However, it is always important to inform your doctor or pharmacist about all medications you are currently taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements. This allows your healthcare team to monitor for any unexpected effects.
| Medication | Type | Clinical Significance |
|---|---|---|
| Follitropin alfa (FSH) | Required co-treatment | Always used together with Luveris. May be mixed in the same syringe for injection. |
| Human chorionic gonadotropin (hCG) | Sequential co-treatment | Administered as a single injection 24-48 hours after the last Luveris/FSH dose to trigger ovulation. |
| Clomiphene citrate | Alternative fertility agent | Not typically used simultaneously. Clomiphene may be used in different treatment protocols. |
| GnRH agonists/antagonists | Pituitary suppression | May be used concurrently in ART protocols to prevent premature LH surge. Does not affect Luveris efficacy. |
What Is the Correct Dosage of Luveris?
The standard dose of Luveris is 75 IU (one vial) injected subcutaneously once daily, given together with 75-150 IU of FSH. Treatment typically lasts up to three weeks but may be extended to five weeks. Dosing is individualized based on ovarian response monitored by ultrasound and blood tests.
Luveris is always used under the supervision of a fertility specialist who is experienced in managing controlled ovarian stimulation. The dosage and duration of treatment are individualized based on your specific clinical situation and ovarian response.
Standard Adult Dosing Protocol
Starting Dose
75 IU Luveris (1 vial) daily plus 75 IU or 150 IU FSH daily, administered by subcutaneous injection.
Dose Adjustment
The FSH dose may be increased by 37.5-75 IU at intervals of 7 to 14 days, based on ovarian response as assessed by ultrasound and serum estradiol levels. The Luveris dose typically remains at 75 IU daily throughout the treatment cycle.
Treatment Duration
Treatment usually lasts up to 3 weeks but may be extended to a maximum of 5 weeks in some patients who respond slowly.
Triggering Ovulation
When adequate follicular development is achieved, a single injection of hCG is administered 24 to 48 hours after the last Luveris and FSH injections. The patient should have intercourse on the day of hCG injection and the following day, or alternatively, IUI or IVF may be performed.
| Parameter | Details |
|---|---|
| Dose | 75 IU subcutaneously once daily |
| Given with | 75-150 IU FSH (follitropin alfa), dose titrated per response |
| Duration | Up to 3 weeks (maximum 5 weeks) |
| Monitoring | Transvaginal ultrasound and serum estradiol levels |
| Ovulation trigger | Single hCG injection 24-48 hours after last Luveris/FSH dose |
| Route | Subcutaneous (abdomen or front of thigh) |
Children and Elderly
Luveris is not indicated for use in children or adolescents under 18 years of age. There is no relevant use in elderly patients, as the medication is specifically intended for women of reproductive age undergoing fertility treatment.
Missed Dose
If you miss a dose of Luveris, do not take a double dose to make up for it. Contact your doctor for advice on how to proceed. Consistency in daily dosing is important for optimal follicular development, and your doctor may need to adjust your monitoring schedule if a dose is missed.
Overdose
The effects of an overdose of Luveris alone are not fully characterized. However, ovarian hyperstimulation syndrome (OHSS) is a theoretical risk following gonadotropin overdose, particularly if hCG is subsequently administered. OHSS would not occur from Luveris overdose alone without an hCG trigger. If you suspect an overdose, contact your doctor immediately.
How Do You Prepare and Inject Luveris?
Luveris is supplied as a powder that must be dissolved in the provided solvent immediately before injection. The reconstituted solution is injected subcutaneously into the abdomen or front of the thigh. Each vial is for single use only.
If you are self-administering Luveris, your doctor or nurse will provide training on the proper reconstitution and injection technique before you begin treatment at home. Always follow these steps carefully to ensure a safe and effective injection.
Step-by-Step Injection Guide
- Wash your hands thoroughly and prepare a clean workspace. Gather all supplies: Luveris powder vial, solvent vial, reconstitution needle, fine subcutaneous needle, syringe, two alcohol swabs, and a sharps container.
- Draw up the solvent: Remove the protective cap from the solvent vial. Attach the reconstitution needle to the syringe, draw up a small amount of air (approximately 1 mL), insert the needle into the solvent vial, push in the air, then invert the vial and carefully draw up all the solvent.
- Dissolve the powder: Remove the cap from the Luveris powder vial and slowly inject the solvent into it. Gently swirl the vial without shaking. The powder usually dissolves immediately.
- Inspect and draw up the solution: Verify that the solution is clear and free of particles. Invert the vial and draw the solution back into the syringe. If your doctor has prescribed both Luveris and follitropin alfa, you can use this solution to dissolve the follitropin alfa powder in its vial.
- Switch to the fine needle: Replace the reconstitution needle with the fine subcutaneous needle. Hold the syringe with the needle pointing upward and gently tap to move air bubbles to the top, then push the plunger to expel them.
- Inject: Clean the chosen injection site (abdomen or front of thigh) with an alcohol swab. Pinch the skin and insert the needle at a 45-90 degree angle in a quick, dart-like motion. Slowly push the plunger to inject the full dose. Withdraw the needle and clean the site with an alcohol swab using a circular motion.
- Dispose safely: Immediately place all used needles and empty glass vials in the sharps container. Any unused solution must be discarded.
What Are the Side Effects of Luveris?
Common side effects of Luveris include headache, nausea, abdominal pain, ovarian cysts, pelvic pain, and injection site reactions. Ovarian hyperstimulation syndrome (OHSS) is a common but potentially serious complication. Allergic reactions are very rare. Contact your doctor immediately if you experience severe abdominal pain, difficulty breathing, or rapid weight gain.
Like all medicines, Luveris can cause side effects, although not everyone experiences them. The side effects listed below are organized by how frequently they occur. Most side effects are mild to moderate and resolve on their own. However, some side effects are serious and require immediate medical attention.
- Severe lower abdominal pain with nausea or vomiting (may indicate OHSS)
- Rapid weight gain or abdominal swelling
- Difficulty breathing or shortness of breath
- Severe allergic reaction: skin rash, facial swelling, hives, breathing difficulty
- Chest pain or sudden leg pain (may indicate blood clot)
Common Side Effects
- Headache
- Nausea, vomiting, diarrhea
- Abdominal pain or discomfort
- Ovarian cysts
- Breast pain or tenderness
- Pelvic pain
- Ovarian hyperstimulation syndrome (OHSS)
- Injection site reactions (pain, itching, bruising, swelling, irritation)
Uncommon Side Effects
- Abdominal bloating or distension
- Fatigue and malaise
- Dizziness
Very Rare Side Effects
- Severe allergic reactions (anaphylaxis) including skin rash, skin redness, hives, facial swelling, or breathing difficulty
- Severe thromboembolic complications (blood clots), usually associated with severe OHSS, which may cause chest pain, shortness of breath, stroke, or heart attack
Ovarian torsion and intra-abdominal bleeding have not been reported specifically with Luveris but have been reported in rare cases with human menopausal gonadotropin (hMG), a urinary-derived preparation that also contains LH activity. These remain theoretical risks with any gonadotropin therapy.
Ectopic pregnancy (pregnancy outside the uterus) may occur, especially in women with a history of tubal disease. Early ultrasound monitoring after a positive pregnancy test helps detect ectopic pregnancies promptly.
How Should You Store Luveris?
Store Luveris at or below 25°C (77°F) in the original packaging to protect from light. Keep out of reach of children. Do not use after the expiration date. Once reconstituted, the solution must be used immediately and cannot be stored.
Proper storage of Luveris is essential to maintain the medication's potency and safety. The powder for injection is sensitive to light and should remain in its original carton until you are ready to prepare the injection.
- Temperature: Store at or below 25°C (77°F). Do not freeze.
- Light protection: Keep in the original packaging to protect from light.
- Expiration date: Check the date on the carton and vial (marked EXP). The expiration date refers to the last day of that month.
- Visual inspection: Do not use the medicine if you notice any discoloration of the powder, particles in the reconstituted solution, or damage to the container.
- After reconstitution: The solution must be used immediately after dissolving the powder. Do not store the reconstituted solution.
- Disposal: Do not dispose of medicines in wastewater or household waste. Return unused medicines to your pharmacy for proper disposal.
What Does Luveris Contain?
Each Luveris vial contains 75 IU of lutropin alfa (recombinant human luteinizing hormone) as the active substance. Inactive ingredients include polysorbate 20, sucrose, sodium dihydrogen phosphate monohydrate, disodium phosphate dihydrate, and L-methionine. The solvent is water for injections.
Active Substance
The active substance in Luveris is lutropin alfa, a recombinant human luteinizing hormone (r-hLH). Each vial of powder contains 75 International Units (IU) of lutropin alfa. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells, resulting in a highly purified glycoprotein that is structurally and functionally equivalent to endogenous human LH.
Inactive Ingredients (Excipients)
| Component | Function |
|---|---|
| Polysorbate 20 | Surfactant (stabilizer) |
| Sucrose | Bulking agent and lyoprotectant |
| Sodium dihydrogen phosphate monohydrate | Buffer (pH stabilization) |
| Disodium phosphate dihydrate | Buffer (pH stabilization) |
| Concentrated phosphoric acid | pH adjustment |
| Sodium hydroxide | pH adjustment |
| L-methionine | Antioxidant (protein stabilizer) |
| Nitrogen | Headspace gas (prevents oxidation) |
| Water for injections | Solvent (1 mL per vial) |
Packaging
Luveris is available in packs containing 1, 3, or 10 vials of powder, each with a corresponding vial of solvent (water for injections). Not all pack sizes may be marketed in your country.
Sodium content: Luveris contains less than 1 mmol (23 mg) of sodium per dose, meaning it is essentially sodium-free.
Marketing Authorization Holder and Manufacturer
Marketing authorization holder: Merck Europe B.V., Gustav Mahlerplein 102, 1082 MA Amsterdam, Netherlands.
Manufacturer: Merck Serono S.p.A., Via delle Magnolie 15, 70026 Modugno (Bari), Italy.
Does Luveris Affect Your Ability to Drive?
Luveris has no or negligible effect on the ability to drive or operate machinery. You can continue your normal daily activities during treatment.
Clinical studies have not identified any impairment of cognitive function, reaction time, or psychomotor performance with Luveris. The medication does not cause drowsiness, dizziness, or visual disturbances that could affect driving ability. You do not need to take any special precautions regarding driving or operating machinery while using Luveris.
Frequently Asked Questions About Luveris
Medical References and Sources
This article is based on current medical research and international guidelines. All claims are supported by scientific evidence from peer-reviewed sources.
- European Medicines Agency (EMA). "Luveris - Summary of Product Characteristics." EMA EPAR - Luveris Authoritative product information approved by the European regulatory authority.
- European Society of Human Reproduction and Embryology (ESHRE) (2024). "Guideline on Ovarian Stimulation for IVF/ICSI." ESHRE Guidelines European clinical practice guidelines for ovarian stimulation protocols.
- Cochrane Database of Systematic Reviews (2023). "Recombinant LH supplementation in assisted reproduction." Systematic review of evidence for LH supplementation during controlled ovarian stimulation. Evidence level: 1A.
- World Health Organization (WHO) (2023). "Infertility: A Global Public Health Issue." WHO Infertility WHO position on infertility management and treatment access.
- American Society for Reproductive Medicine (ASRM) Practice Committee (2023). "Use of exogenous gonadotropins in anovulatory women." ASRM Practice Documents American clinical guidelines for gonadotropin use in anovulatory infertility.
- Bosch E, et al. (2021). "Recombinant human luteinizing hormone supplementation in assisted reproductive technology: a systematic review." Fertility and Sterility. 115(5):1128-1137. Comprehensive review of clinical evidence for r-hLH in ART.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in reproductive endocrinology, clinical pharmacology, gynecology, and internal medicine.